feedback

Course Director

Pravin U. Dugel, MD
Pravin U. Dugel, MD

Retinal Consultants of Arizona LTD
Retinal Research Institute LLC
Phoenix Eye Institute
Banner University Medical Center
Phoenix, Arizona

USC Roski Eye Institute
Keck School of Medicine
University of Southern California
Los Angeles, California

Faculty

David S. Boyer
David S. Boyer, MD

Retina-Vitreous Associates Medical Group
USC/Keck School of Medicine
Los Angeles, California

Peter K. Kaiser
Peter K. Kaiser, MD

Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Jun-11
Expiration Date:2019-Jun-10
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, which is based on a live symposium held at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology, experts in retinal diseases discuss the diagnosis and treatment of patients with neovascular age-related macular degeneration, including the potential clinical impact of emerging agents.

Upon completion of this activity, participants should be better able to:
  • Apply strategies to identify patients with or at risk for neovascular AMD in clinical practice
  • Employ individualized evidence-based treatment approaches for patients with neovascular AMD
  • Identify emerging treatments for neovascular AMD in terms of mechanism of action, efficacy, and safety

Target Audience

This activity has been designed to meet the educational needs of comprehensive ophthalmologists, retina specialists, and other clinicians involved in the management of patients with age-related macular degeneration.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 11, 2018 - June 10, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Pravin U. Dugel, MD
Managing Partner
Retinal Consultants of Arizona LTD
Retinal Research Institute LLC
Physician Executive Director
Phoenix Eye Institute
Banner University Medical Center
Phoenix, Arizona

Clinical Professor
USC Roski Eye Institute
Keck School of Medicine
University of Southern California
Los Angeles, California

Pravin U. Dugel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott/AMO Pharm; Acucela Inc.; Aerpio; Alcon Pharmaceutical; Alcon Surgical (RACII); Alimera Sciences; Allergan; Annidis Corporation; ArcticDx Inc.; Bausch & Lomb Incorporated (Pharma and Surgical); Boehringer Ingelheim GmbH; ByeOnics; Chengdu Kanghong Biotechnology Co. Ltd; Clearside BioMedical, Inc.; DigiSight Technologies Inc.; DOSE Medical Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Graybug Vision, Inc.; Irenix Medical, Inc.; Kodiak Sciences Inc.; Lutronic; Lux Biosciences, Inc.; MacuSight, Inc.; NeoVista Inc.; Neurotech; Novartis Pharmaceuticals Corporation; Omeros Corporation; Ophthotech Corporation; Opthea; Optovue, Incorporated; Ora, Inc.; PanOptica; Pentavision; QLT, Inc.; Regeneron; Santen Pharmaceutical Co., Ltd; SciFluor Life Sciences, Inc.; Shire; Spark Therapeutics, Inc.; Stealth BioTherapeutics Inc.; ThromboGenics NV; and Topcon Corporation.
Stock Shareholder in Aerpio; Alimera Sciences; Annidis Corporation; ArcticDx Inc.; Clearside BioMedical, Inc.; DigiSight Technologies Inc.; Irenix Medical, Inc.; Ophthotech Corporation; and PanOptica.
Advisory Board for Acucela Inc.; Aerpio; Alcon Pharmaceutical; Alcon Surgical (RACII); Alimera Sciences; AMO Pharm; Annidis Corporation; ArcticDx Inc.; Avalanche Biotechnologies, Inc; CDR-Life Inc.; Clearside BioMedical, Inc.; DigiSight Technologies Inc.; DOSE Medical Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Graybug Vision, Inc.; Lutronic; Lux Biosciences, Inc.; MacuSight, Inc.; NeoVista Inc.; Neurotech; Novartis Pharmaceuticals Corporation; Omeros Corporation; Ophthotech Corporation; Opthea; Orbis Biosciences, Inc.; Santen Pharmaceutical Co., Ltd.; Shire; Stealth BioTherapeutics Inc.; ThromboGenics NV.; and TrueVision.

Faculty

David S. Boyer, MD
Sr. Partner, Retina-Vitreous Associates Medical Group
Clinical Professor of Ophthalmology
USC/Keck School of Medicine
Los Angeles, California

David S. Boyer, MD, has a financial interest/relationship or affiliation in the form of:
Stock Shareholder in Allegro Ophthalmics, LLC.
Consultant and/or Advisor for Alcon; Allegro Ophthalmics, LLC; Bausch & Lomb Incorporated; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Glaukos Corporation; Novartis Pharmaceuticals Corporation; Ophthotech Corporation; Optos plc; Optovue, Incorporated; Regeneron Pharmaceuticals, Inc.; Shire; and Sun Pharmaceutical Industries Ltd.

Peter K. Kaiser, MD
Cole Eye Institute
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Peter K. Kaiser, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aerie Pharmaceuticals; Aerpio; Alcon; Allegro Ophthalmics, LLC.; Allergan; Bayer Corporation; Biogen; Boehringer Ingelheim GmbH; Chengdu Kanghong Pharmaceutical Group Co Ltd; Galecto Biotech AB; Hospira Inc.; jCyte; Kodiak Sciences Inc.; Novartis Pharmaceuticals Corporation; Ohr Pharmaceutical; Omeros Corporation; Regeneron; Retinal Sciences; Santen Pharmaceutical Co., Ltd.; Shire; SciFluor Life Sciences; Spark Therapeutics, Inc.; Stealth BioTherapeutics Inc.; and ThromboGenics NV.

Medical Director

Kate Nelson, PhD
PVI, PeerView Institute for Medical Education

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6295-18-T.

Providership


This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.